Role of aggressive surgical cytoreduction in advanced ovarian cancer / 부인종양
Journal of Gynecologic Oncology
;
: 336-342, 2015.
Artigo
em Inglês
| WPRIM
| ID: wpr-123432
ABSTRACT
Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Ovarianas
/
Padrões de Prática Médica
/
Variações Dependentes do Observador
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Estudos Retrospectivos
/
Neoplasia Residual
/
Medicina Baseada em Evidências
/
Procedimentos Cirúrgicos de Citorredução
Tipo de estudo:
Estudo observacional
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Journal of Gynecologic Oncology
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS